Quick summary
Somatostatin is an endogenous cyclic peptide (SST-14 and SST-28 isoforms) that broadly inhibits hormone secretion including GH, insulin, glucagon, and gastrin. Its ultrashort 1-3 minute half-life drove development of clinical analogs octreotide, lanreotide, and pasireotide.
Overview
Somatostatin is an endogenous cyclic peptide existing in 14-amino acid (SST-14) and 28-amino acid (SST-28) isoforms. Produced in the hypothalamus, pancreas, and gastrointestinal tract, it broadly inhibits hormone secretion and serves as the structural template for octreotide, lanreotide, and pasireotide. Its ultrashort half-life drove development of longer-acting analogs.
Mechanism of action
Somatostatin binds five G-protein-coupled receptor subtypes (SSTR1–5) expressed throughout the brain, pituitary, pancreas, and gut. Receptor activation inhibits adenylyl cyclase, reduces intracellular cAMP, inhibits voltage-gated calcium channels, and activates inward-rectifier potassium channels. Net effect is broad inhibition of GH, insulin, glucagon, gastrin, secretin, TSH, and prolactin secretion. SST-14 preferentially binds SSTR1–4; SST-28 has higher affinity for SSTR5.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| research / GI bleed (off-label clinical use) | intravenous | 250–500 mcg/hr | continuous infusion | Used investigationally; analogs preferred in clinical practice due to superior half-life |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Somatostatin's multi-tissue expression and broad inhibitory profile have made it a cornerstone of endocrine physiology research. Its 1–3 minute half-life in vivo limits therapeutic utility; however, all clinically approved somatostatin analogs (octreotide, lanreotide, pasireotide) are derived from its pharmacophore. Research continues into SSTR-subtype selective agonists for targeting specific tumors, including NETs and pituitary adenomas.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Somatostatin for synergistic effects.
Legal status
Native somatostatin is used in research and as an IV infusion in some clinical protocols outside the US. Synthetic long-acting analogs are the approved clinical agents. Not FDA-approved as a standalone drug.
Sourcing & access
Research compound
Somatostatin is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Somatostatin is an endogenous cyclic peptide produced in the hypothalamus, pancreas, and GI tract. It exists as 14-amino acid (SST-14) and 28-amino acid (SST-28) isoforms and broadly inhibits the secretion of growth hormone, insulin, glucagon, gastrin, and other hormones.
Somatostatin binds five G-protein-coupled receptor subtypes (SSTR1-5) throughout the brain, pituitary, pancreas, and gut. Receptor activation inhibits adenylyl cyclase, reduces cAMP, inhibits calcium channels, and activates potassium channels, resulting in broad hormone secretion suppression.
Side effects include rebound hypersecretion on discontinuation, GI cramping, nausea, and rare hypoglycemia. Its extremely short half-life of 1-3 minutes limits therapeutic use, which is why longer-acting synthetic analogs are preferred clinically.
Octreotide, lanreotide, and pasireotide are FDA-approved synthetic analogs derived from somatostatin's pharmacophore, each engineered with substantially longer half-lives than the endogenous 1–3 minute peptide. Octreotide and lanreotide (SSTR2/SSTR5-selective) are used for acromegaly, gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome; pasireotide adds SSTR1/SSTR3 affinity and is approved for Cushing's disease resistant to surgery.
Research references
- Primary structure of somatostatin, a hypothalamic peptide that inhibits the secretion of pituitary growth hormonePubMed
- International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclatureReview
- Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective studyClinicalTrials.gov
- The role(s) of somatostatin, structurally related peptides and somatostatin receptors in the gastrointestinal tract: a reviewReview
- Medical therapy of acromegaly: efficacy and safety of somatostatin analoguesReview